Review

Oleuropein Aglycone: A Possible Drug against Degenerative Conditions. In Vivo Evidence of its Effectiveness against Alzheimer’s Disease

Fiorella Casamenti¹*, Cristina Grossi², Stefania Rigacci³, Daniela Pantano³, Ilaria Luccarini³ and Massimo Stefanib

¹Department of Neuroscience, Psychology, Drug Research and Child Health, Division of Pharmacology and Toxicology, University of Florence, Florence, Italy
²Department of Experimental and Clinical Biomedical Sciences “Mario Serio”, University of Florence, Florence, Italy

Accepted 19 December 2014

Abstract. The amyloid plaques and neurofibrillary tangles found in the Alzheimer’s disease (AD) brain arise as a result of self-assembly into fibrillar material of amyloid-β protein (Aβ) and hyperphosphorylated tau, respectively, through a pathological process starting with the appearance of aggregation nuclei and neurotoxic oligomers. Accordingly, the search of inhibitors of oligomer nucleation and growth is considered a promising target to prevent amyloid toxicity. In recent years, a number of dietary factors including antioxidants, vitamins, and polyphenols have been characterized for their ability to protect cells stressed by several factors including the presence of amyloid deposits as well as to inhibit amyloid self-assembly and cytotoxicity and some of them are currently in clinical trial. The present review summarizes the findings on the beneficial effects against neurodegeneration and other peripheral inflammatory and degenerative diseases of oleuropein aglycone (OLE), a natural phenol abundant in the extra virgin olive oil. The data presently available suggest that OLE could provide a protective and therapeutic effect against a number of pathologies, including AD as well as obesity, type 2 diabetes, non-alcoholic hepatitis, and other natural or experimentally-induced pathological conditions. Such a protection could result, at least in part, in a remarkable improvement of the pathological signs arising from stress conditions including oxidative stress, an excessive inflammatory response, and the presence of cytotoxic aggregated material. In particular, the recent data on the cellular and molecular correlates of OLE neuroprotection suggest it could also play a therapeutic role against AD.

Keywords: Alzheimer’s disease, amyloid-β deposits, autophagy, epigenetics, polyphenols, TgCRND8 mice

INTRODUCTION

Focusing dietary regimens associated with a reduced risk of degenerative diseases in the aged population can be useful to find molecules exploitable for their prevention and therapy. Mounting evidence supports the beneficial effects of the Mediterranean and Asian diets in delaying aging and in preventing age-related
OLE COUNTERACTS THE SIGNS OF A NUMBER OF DEGENERATIVE CONDITIONS RESULTING FROM OXIDATIVE STRESS AND INFLAMMATION

Previous studies carried out in vivo such as those performed with mice models of spinal cord injury [19], carrageenan-induced pleurisy [20], collagen-induced arthritis [21], and intestinal ischemia-reperfusion injury [22] have shown that OLE possesses remarkable anti-inflammatory activity [23]. Other studies have indicated that OLE possesses other biochemical and pharmacological activities, including cardioprotective, antioxidant, antitherogenic, anticancer, antimicrobial, and antiviral effects (reviewed in [24]). Finally, it has been reported that OLE and other polyphenols found in olive oil are able to prevent low density lipoprotein oxidation and platelet aggregation and to inhibit lipooxygenase and eicosanoid production [25]. For all these reasons in recent years OLE has become an important subject of study. In particular, the effects of OLE and other natural polyphenols on living systems recall those produced by a healthy level of caloric restriction, which is recommended to improve aging reducing the risk of age-associated diseases, including dementia. These similarities have led to propose that the beneficial effects of the Mediterranean/Asian diets result from their rich content of polyphenols [26].

OLE PROTECTS AGAINST TYPE 2 DIABETES AND OTHER CONDITIONS THAT CHARACTERIZE THE METABOLIC SYNDROME

Besides the protective effects against a number of pathologies with uncontrolled oxidative stress and inflammatory reaction outlined above, recent research has shown the effectiveness of OLE against obesity [27], type 2 diabetes [28] and the hepatic steatosis induced by a high-fat diet in mice [29]. Taken together, these data support a beneficial action of OLE against some of the signs of the metabolic syndrome, a complex pathological condition affecting an increasing number of people in advanced countries. In particular, OLE supplementation to high-fat diet mice reversed the increase of liver weight together with that of hepatic and plasma lipid levels; this occurred possibly through downregulation of the expression of Wnt10b-inhibitor genes and the Toll-like receptor-mediated signaling molecules (TLR2, TLR4) and pro-inflammatory cytokines. The expression of several transcription factors and their target genes involved in adipogenesis, was also downregulated, whereas the expression of β-catenin was upregulated [29]. These results have led these authors to suggest that OLE protects against high fat-induced hepatic steatosis in mice through Wnt10b- and fibroblast growth factor receptor-1 (FGF1)-mediated signaling involved in liver lipogenesis together with TLR2 and TLR4 signaling involved in hepatic steatosis.

A recent randomized, double-blind, placebo-controlled crossover trial was carried out in New
Zealand with 46 middle-aged participants, with medium-high body-mass index and at risk of developing the metabolic syndrome, receiving an oral dose of OLE (50 mg+10 mg hydroxythyrosol) or of placebo for 12 weeks. At the end of the treatment, the results showed that, as compared to placebo, people fed with OLE displayed a 15% improvement in insulin sensitivity and a 28% improvement of pancreatic β-cell responsiveness and secretory capacity, with increased concentrations of interleukin 6 (IL-6) and insulin-like growth factor-binding protein 1/2 (IGFBP-1/2), without any evident negative effect on hepatic and other physiological parameters [28]. Taken together, these data agree with those previously reported on OLE interference with the normal path of amylin aggregation in vitro with lack of appearance of cytotoxic oligomers [15].

**PLANT POLYPHENOLS ARE EFFECTIVE AGAINST ALZHEIMER’S DISEASE**

AD is the most common form of dementia presently affecting, in developed countries, approximately 30 million aged people, and those numbers are expected to triple by 2050. The key histopathological sign of AD is the presence, in several brain areas, of hyperphosphorylated tau aggregates and tangles, of minute extracellular amyloid (Aβ) deposits found in diffuse and senile plaques and around cerebral vessels and dystrophic/degenerating neurites. Plaque deposits, mainly composed of polymeric fibrils of the 42 amino acid peptide (Aβ42) generated by membrane amyloid-β protein precursor proteolysis [30, 31], are thought to be responsible for the functional alterations and behavioral deficits that characterize AD [30]. Recently, the interest in deciphering the relationship between plaque burden and neuronal death has focused on the importance, as the main neurotoxic species, of the oligomeric pre-fibrillar assemblies originating at the onset of fibril growth [32]. The latter evidence contributed to explain the lack of relation between plaque load and AD severity [33]; it also shifted the search of treatments able to delay AD occurrence and to relieve its symptoms from the development of molecules able to hinder fibril growth to that of molecules effective in counteracting the appearance of toxic oligomeric intermediates [34]. Several therapeutic approaches inhibiting amyloidogenic protein self-assembly into oligomers and fibrils are under development; in particular, increasing interest is devoted to the anti-amyloidogenic activity of plant polyphenols present in several foods such as resveratrol, OLE, curcumin, and epigallocatechin-3-gallate [8]. In particular, recent work has provided the most complete set of data concerning the beneficial effects of OLE [5, 7, 17, 18]. These include the behavioral, biological, biophysical, biochemical, and electrophysiological correlates of OLE protection against neurodegeneration which characterizes AD.

**OLE REDUCES COGNITIVE IMPAIRMENT AND IMPROVES SYNAPTIC FUNCTION IN TgCRND8 MICE**

The beneficial effects of dietary supplementation of OLE were investigated in the TgCRND8 (Tg) mice, a widely used model of Aβ deposition [5, 18]. These Tg mice are cognitively impaired by the age of 3 months [35] and develop a pattern of Aβ deposition recalling several aspects of human AD [36, 37]. By the same age, mice display small sized Aβ40-immunopositive plaques in various brain areas, including the cortex and the hippocampus. Upon aging, plaque number increases, reaching the maximum roughly by 7–9 months of age; moreover, the plaques become larger, from small-medium to big in size and radiating in shape and acquire a compact core [36]. In addition, in later life stages, from 6 to 12 months of age, this Tg strain exhibits, throughout the cortical and hippocampal areas, plaques with a huge amount of pyroglutamylated 3-42Aβ (pE3-Aβ) largely exceeding that of Aβ42 [18]. This Aβ42 derivative is produced by the activity of glutaminyl cyclase (QC) and is increasingly considered a key player in Aβ aggregation and plaque growth [38]. Two types of pE-Aβ plaques are found in the human hippocampus, focal and diffuse, the former associated with QC-expressing interneurons [39] thus supporting the close pE-Aβ/QC relation and its association with cognitive decline in AD [40]. Moreover, the finding that QC expression and pE-Aβ burden increase with Braak stages [41] further stresses the importance of these factors in AD pathogenesis.

Wild type (wt) and Tg mice of three age groups (1.5, 4.0 and 10.0 months) were treated for 8 weeks with a modified low-fat (5.0%) AIN-76A diet either as such (untreated mice) or supplemented with 50 mg OLE/kg of diet (OLE-fed mice) [5], following DL 1160/92. Directive 86/609/EEC and National guidelines for animal care (P.N. 283/2012-B). At the end of treatment, the wt and Tg mice were checked for cognitive performance. Untreated 3–6-month-old Tg mice were unable to memorize the punishment and to perform the inhibitory avoidance in the step-down
passive avoidance test; they were also unable to discriminate between the familiar and the novel object in the object recognition test [5]. However, OLE-fed mice displayed a remarkable improvement in both behavioral tests, with scores reaching those displayed by age-matched wt controls. The improved results in cognitive tests were associated with a significant amelioration of synaptic function, as assessed by long-term potentiation experiments in CA1 hippocampal slices of aged Tg mice incubated with OLE or with vehicle 1 h before and during all electrophysiological recordings [18]. Interestingly, similar results were obtained with slices exposed to suberoylanilide hydroxamic acid (SAHA), an histone deacetylase-2 inhibitor, suggesting some epigenetic involvement (see below).

OLE REDUCES SOLUBLE Aβ PLAQUE LOAD/DENSITY, AND GLIA REACTION IN TgCRND8 MICE

The improvement of OLE-fed Tg mice in cognitive tests was accompanied by a significant reduction of Aβ40 and Aβ42 and pE3-Aβ levels in the brain tissue, in agreement with the in vitro anti-aggregation effect of OLE [7, 18]. In the older Tg mice, OLE administration not only prevented amyloid deposition but also favored disaggregation of preformed plaques [5], that appeared “fluffy” and less cored in the neuron surroundings (Fig. 1). In the hippocampus and cortices of 12-month-old OLE-fed Tg mice, Thioflavin S staining, which marks Aβ fibrils, revealed a significant reduction in the number and total Aβ plaque area (Fig. 2A, B); moreover, most plaques displayed reduced size and a ribbon-like/diffuse core, as compared to those imaged in untreated Tg mice. As we already reported employing OC and pE3-Aβ antibodies [18], in both OLE-fed and untreated 12-month-old Tg mice an overlap of the staining of the pE3-Aβ (blue) and Thioflavin S (green) was detected in the entire plaque where pE3-Aβ blue staining was particularly intense in the plaque core (Fig. 2A). This effect was also the consequence of a significant reduction of QC expression in the brain of OLE-fed mice, whereas the polyphenol had no effect on QC activity in vitro [18]. The molecular mechanism of this finding has not been determined; however, it appears to be of critical importance to drive the beneficial effects of OLE associated with plaque load reduction.

As already reported for young/middle-aged Tg mice [5], Aβ40 and Aβ42 sodium dodecyl sulphate and formic acid soluble fractions measured in the cortex of 12-month-old OLE-fed Tg mice were significantly reduced as compared to untreated Tg mice (Fig. 2C). Furthermore, in the aged OLE-fed Tg mice, the decreased Aβ load was paralleled by a less intense Aβ-associated glia reaction, in terms of reduced astrocyte activation, as shown by the presence of fewer and less reactive astrocytes throughout the brain and reduced glial fibrillary acidic protein levels (Fig. 3).

OLE TRIGGERS AUTOPHAGY

In AD, plaque load results from complex equilibria between Aβ deposition and clearance, where

Fig. 1. Representative photomicrographs showing neurons (green) within compact and fluffy amyloid plaques, stained by OC antibody (red), in untreated and OLE-administered TgCRND8 mice.
Fig. 2. Thioflavin S staining in untreated and OLE-fed TgCRND8 mice. A) OLE administration reduces Thioflavin S positive plaque burden (green) in the hemibrain of 12-month-old TgCRND8 mice; pE3-Aβ (blue) and Thioflavin S (green) staining co-localizes in cored Aβ deposits of both Tg groups. B) Quantitative analysis of Thioflavin S stained plaque area and plaque number in 12-month-old untreated and OLE-fed Tg mice (n = 5/group, six sections/mouse) in the parietal and piriform cortices and in the hippocampus (squared areas indicate in the left hemibrain image). C) ELISA: cortical levels of sodium dodecyl sulphate- and formic acid-soluble Aβ40 and Aβ42 peptides. Both Aβ40 and Aβ42 levels were significantly decreased in OLE-fed Tg versus age-matched untreated Tg mice (n = 5/group). Data are reported as mean values ± S.E.M. Statistical analysis: two-tailed unpaired Student’s t-test.
Fig. 3. Glial fibrillary acidic protein (GFAP) immunoreactivity and levels in untreated and OLE-fed TgCRND8 mice. A) Left panels, reconstruction of representative photomicrographs of GFAP immunoreactivity in the cortex and hippocampus of 12-month-old untreated and OLE-treated Tg mice. Right panels: hypertrophic astrocytes (green) with long and thick branches were detected in the brains of untreated Tg mice in the plaque (red, OC antibody) surroundings. In OLE-fed animals astrocyte (green) activation in the fluffy plaque (red, OC antibody) surroundings was considerably milder. B) Western blotting quantitative analysis of GFAP levels in the hippocampus of 12-month-old OLE-fed Tg and untreated wt and Tg mice, n = 5-6 mice/group (*p < 0.05, wt versus Tg OLE; **p < 0.01 wt versus Tg; One Way ANOVA plus Newman-Keuls Multiple Comparison Test).

Autophagy (namely macroautophagy), a mammalian target of rapamycin (mTOR)-dependent lysosome-mediated catabolic pathway responsible for turnover of long-lived proteins and organelles, appears to play a key role. Autophagy protects neurons against environmental stresses such as starvation and Aβ-induced cytotoxicity, suggesting its possible role in Aβ clearance. The picture is made even more complex by the data showing that increased mTOR signaling, and hence depressed autophagy, seems to be induced by Aβ peptides; accordingly, it has been suggested that Aβ-mediated mTOR activation could contribute to early cognitive deficits in AD. These and other data support the notion that autophagic dysfunction may represent a key molecular link between brain aging, Aβ accumulation in the brain parenchyma, and cognitive impairment. By contrast, autophagy stimulation [43] or reversal of autophagy dysfunction by different treatments has been shown to ameliorate amyloid pathologies [42] such that it is increasingly recognized that induction of autophagy might be useful to protect against neurodegeneration and Aβ peptide toxicity [44, 45].

We have recently found a remarkable induction of the autophagic pathway in the cortex of OLE-fed young and old Tg mice. In these animals, OLE administration triggers the autophagic machinery and favors autophagosome substrate delivery to lysosomes for cargo degradation [18]. Specifically, a strong punctate immunoreactivity and higher levels of autophagosome-lysosome markers such as Beclin-1, the lipidated derivative of LC3 and cathepsin B, were detected in the cortex and, to a lesser extent, in hippocampal areas of OLE-fed Tg mice at all stages of the pathology, as compared to untreated age-matched controls [5, 18]. Although to a lesser extent than in OLE-fed Tg mice, Beclin-1 and LC3 immunoreactivities were also more intense in OLE-fed wt mice than in untreated animals, supporting a general effect of OLE as an autophagy inducer.

Various signaling pathways are involved in macroautophagy stimulation. As pointed out above, the canonical pathway involves mTOR Complex 1 (mTORC1), a cytosolic complex of five proteins including mTOR, a primordial negative regulator of autophagy. mTOR is inhibited by stress conditions
Fig. 4. Schematic representation of effects and cellular targets of OLE in TgCRND8 mice.

such as starvation that result in activation of mTOR targets. mTOR inhibitors such as rapamycin display similar effects, leading to propose it as a new tool to fight neurodegeneration [43]. Autophagy can be triggered also by mTOR inhibition through phosphorylation by AMP-activated protein kinase (AMPK), a stress-induced kinase activated by phosphorylation triggered with a number of signals associated with cellular energy homeostasis such as an increase of the AMP/ATP ratio and the serine/threonine kinase liver kinase B1 (LKB1) [47]. AMPK can also be activated by a rise of the cytosolic Ca$^{2+}$. The resulting Ca$^{2+}$/calmodulin complex activates the calcium/calmodulin-dependent protein kinase 2 (CAMKK2), a kinase expressed in the CNS where it plays key roles in axon and synaptic plasticity; in turn,
the activated CAMKK activates AMPK by phosphorylation [48]. In our mouse model, autophagy activation by OLE could not directly involve mTOR; in fact, our unpublished data with OLE-exposed cultured SHSY-5Y cells suggest that in these cells of neuronal type autophagy is triggered following AMPK activation.

**OLE MODULATES EPIGENETICS IN Tg MICE**

Accumulating evidence indicates epigenetic deregulation (DNA methylation, histone methylation, acetylation, and phosphorylation) of gene expression in many pathological states, from cancer to cardiovascular diseases and metabolic disorders; in particular, epigenetics appear to play an important role in age-related memory impairment and in the pathogenesis of neurodegenerative diseases. In particular, proper levels of histone acetylation appear of the utmost importance to delay aging and to hinder neurodegeneration. Histone acetylation is thought to be associated with an “open” chromatin conformation and transcriptional activation, while histone deacetylation is considered to be involved in transcriptional repression resulting from a “closed” chromatin structure [49]. Histone acetylation levels are the result of a balance between the activities of histone acetyltransferases and histone deacetylases (HDACs). Abnormal acetylation of histones is involved in learning and memory and might be causally associated to AD pathogenesis [50]; moreover, histone acetylation seems to ameliorate cognitive deficits in AD animal models [51]. In particular, HDACs, isoform 2, appear to be upregulated in the AD brain, thus reducing the level of histone acetylation and blocking DNA transcription at specific loci. In AD brains, the HDAC2 levels are increased [50] and the balance of histone 3 acetylation is disrupted by soluble Aβ [52].

The above reported results concerning remarkable modifications of the expression of QC and autophagy markers in our OLE-fed Tg mice, together with the effect of SAHA in restoring long-term potentiation in hippocampal slices mimicking that resulting from OLE exposure, supported some involvement of epigenetic modulations by OLE [18]. Our initial study on the OLE-epigenetics relationship has shown that in our TgCRND8 mice HDAC2 expression is increased concomitantly with the reduction of histone 3 and 4 acetylation throughout the cortex and the hippocampus, both contributing to their cognitive impairments and synaptic dysfunctions. Those modifications were fully reverted by OLE treatment [18], even though the mechanistic basis of this effect has not been elucidated yet. Our data support the idea that epigenetic mechanisms, particularly some modification of the histone acetylation level, underlie the neuroprotective effects of OLE and, therefore, can be considered as a new approach to prevent and, possibly, to treat AD patients. On the other hand, presently AD treatments are limited to symptomatic relief, whereas effective therapy is not available yet. Our findings agree with recent data suggesting that the development of effective HDAC inhibitors could be a new promising therapeutic strategy to fight AD [51].

**CONCLUSIONS**

The beneficial effects of the Mediterranean and Asian diets stem from many factors. An important role is increasingly attributed to the content of polyphenols of several foods, including olive oil, red wine, green tea, and spices. Differently from resveratrol, curcumin, and epigallocatechin-3-gallocate, extensively studied for their healthy properties, much less knowledge is available on olive oil polyphenols, including OLE. However, recent findings from our and other groups have addressed this theme providing valuable data on the molecular and cellular basis of the beneficial effects of these polyphenols against type 2 diabetes [53], liver steatosis [29], obesity [27], and age-associated neurodegeneration [9].

For what Aβ-induced neurodegeneration is concerned, recently reported findings indicate that OLE administration to Tg mice improves memory and behavioral performance by interfering with Aβ aggreagation and restoring the transgene-associated different dysfunctional aspects in the brain of our mouse model of AD. The identified cellular targets include plaque deposition, size, and compactness, the pE3-Aβ/Aβ42 ratio, the inflammatory and the autophagic/lysosomal responses, epigenetics, and the synaptic function (Fig. 4). In conclusion, our results suggest that OLE supplementation could be considered as a new approach to prevent, to delay, and, possibly, to treat AD.

**ACKNOWLEDGMENTS**

Supported by the Regione Toscana: “Programma per la Ricerca Regionale in Materia di Salute 2009”, by the ECRF 2010-2011 and the Università degli Studi di Firenze.
Authors’ disclosures available online (http://j-alz.com/manuscript-disclosures/14-2850tr1).

REFERENCES


